Published 24 Oct 2023Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.
Genomics plc has been included in Bloomberg’s 25 UK Startups to Watch list. The list spans the tech sector and startup scene. Genomics plc co-Founder, Professor Sir Peter Donnelly, will be one of three the founders of companies featured in the list on stage at today’s Bloomberg Technology Summit to discuss Genomics and the wider life sciences/tech sector.
Genomics plc was spun out of the University of Oxford in 2014 and uses its extensive data platform and cutting-edge analytical technology to enable prevention-first approaches to individual and population health. Its powerful risk prediction tools can get more of the right people into the appropriate screening, diagnosis, and treatment pathways they need. Genomics’ also supports the life sciences sector in the discovery and validation of new drug targets, and optimized clinical trial design and efficiency.
The inaugural Bloomberg Startups to Watch list canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. Bloomberg looked for the most innovative, new UK businesses to feature. It wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Editors considered a number of criteria when assessing the entries including: the scope of the problem they're tackling, creativity of ideas, the traction they're getting with investors and customers, and their commitment to diversity. Bloomberg received more than 1,500 applications.
Genomics plc has contracts with several pharmaceutical and insurance companies, including MassMutual. Genomics plc is also the exclusive provider of PRS to the UK’s Our Future Health programme, which is recruiting up to 5 million participants to test and develop new ways to prevent, detect and treat common diseases. In 2022, Genomics plc partnered with the NHS to run the HEART Trial - the world’s first real-world pilot using genomics to help improve cardiovascular disease prevention in GP practices in England - GPs said they would change the management of 13% of their patients based on the new assessment.
Professor Sir Peter Donnelly FRS, FMedSci, Founder and Chief Executive Officer, Genomics plc:
“We are delighted to have been recognised by Bloomberg as one of the most innovative UK startups, and events like this help to shine a light on the great work we are doing. The UK continues to be an attractive location for global life sciences companies to invest and innovate and genomics has a significant role to play in the future of healthcare. We are excited to be leading the way in development of polygenic risk score-based tools here in the UK and overseas.”